Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...
Primary aldosteronism management depends on a multitude of factors, and surgical adrenalectomy is generally recommended in ...
Detailed price information for Cspc Pharmaceuticals Group Ltd (CHJTF) from The Globe and Mail including charting and trades.
AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension: Our Bureau, Bengaluru Monday, January 5, 2026, 18:0 ...
It doesn’t take a rocket ― er, dick scientist ― to know that it’s not just whiskey that causes whiskey dick. Vodka drinkers ...
Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million.
An announcement from Mineralys Therapeutics, Inc. ( ($MLYS) ) is now available. On January 6, 2026, Mineralys Therapeutics provided a corporate ...
Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a ...
Sodium-glucose cotransporter 2 inhibitors (eg, dapagliflozin) are understudied in kidney transplant recipients. A trial attempted to fill this knowledge gap.
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of ...
Detailed price information for Cspc Pharmaceuticals Group Ltd (CHJTF) from The Globe and Mail including charting and trades.
Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback